Dr. Nouran Hamza, BPharm, MSc, PhD is a biostatistician, epidemiologist, and clinical research methodologist with extensive experience in real-world evidence (RWE), epidemiological research, and statistical methodology for clinical studies. She contributes to the Amyloidosis Africa initiative by supporting research methodology, data analysis strategies, and evidence generation efforts aimed at improving the recognition and understanding of cardiac amyloidosis across Africa.

Dr. Hamza has worked on research and capacity-building initiatives across more than 20 countries, focusing on strengthening the methodological rigor of epidemiological studies, clinical trials, and health systems research. She specializes in biostatistics, real-world evidence generation, study design, and strategic analysis for healthcare research and public health initiatives.

She is the Founder and Managing Director of MARS-Global, a clinical research consultancy focused on rare disease research, real-world evidence generation, and scientific publications. She also serves as CEO and Co-Founder of CRK Clinical Research Organization, an NGO-based clinical research organization working to improve access to high-quality healthcare research for underserved communities.

Dr. Hamza holds a PhD in Biostatistics from the University of Cambridge, a Master’s degree in Public Health from Alexandria University, and a Bachelor of Pharmacy from October 6 University. Her academic and professional work focuses on translating complex data into decision-grade evidence that informs clinical research, healthcare policy, and patient care strategies.

Through her work with Amyloidosis Africa, Dr. Hamza contributes to strengthening research design, data governance, and evidence generation to support collaborative studies and improve awareness and early diagnosis of cardiac amyloidosis across the African continent.